A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Hartmut Döhner, MD
Universitätsklinikum Ulm
Principal Investigator - Ipsen Medical Director
Ipsen
Study Director - Mojca Jongen-Lavrencic, MD
Erasmus Medical Center
Principal Investigator - Raoul Tibes, MD
Mayo Clinic Scottsdale-Phoenix
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Universitätsklinikum Ulm
Ulm, Germany
- Erasmus University Medical Center
Rotterdam, Netherlands
- Mayo Clinic Scottsdale-Phoenix
Scottsdale, Arizona, United States
- Northwestern University
Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Duke University Health System
Durham, North Carolina, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Ut Md Anderson Cancer
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2012
- Primary completion
- 30 Nov 2015
- Completion
- 29 Feb 2016
- Last update posted
- 26 Mar 2024
- Registered enrollment
- 51
- Registry id
- NCT01684150
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.